Eli Lilly and Company announced plans to invest more than $1 billion over the next several years in contract manufacturing partnerships across India, marking a significant expansion of the company’s global manufacturing footprint and its commitment to the country’s pharmaceutical
Carole Delauney warns that sterile injectable manufacturing “is not just fill-finish”—a misconception that can cost biotech companies millions and even derail entire drug development programs. She notes, “This is unfortunately not commonly recognized in the industry, but it is a
President Donald Trump has delayed implementing threatened 100% tariffs on branded pharmaceutical products as his administration pursues negotiated drug pricing agreements with major manufacturers, according to White House officials. The administration paused its plan to enact the duties, originally scheduled
Contract development and manufacturing invested a disclosed amount of $7.2 billion in September 2025—with 97% flowing to US facilities—as the sector’s reshoring momentum reached the highest level of the year so far. PharmaSource tracks every significant CDMO announcement globally—partnerships, investments,
In a 60-second interview with PharmaSource, Jürgen Wagner, the newly appointed General Manager of Ophtapharm AG, outlined his vision for the Swiss contract manufacturing organization as it enters a new phase of growth in sterile ophthalmic manufacturing. Jürgen, who took
The deal, announced September 30, 2025, will make participating Pfizer products available through TrumpRx, a newly launched federal drug purchasing website. The White House positioned the Pfizer partnership as the inaugural implementation of the May 2025 executive order aimed at
Amgen has announced a $650 million expansion of its US manufacturing network, creating nearly 750 new jobs at its biologics manufacturing facility in Juncos, Puerto Rico. The investment will support increased drug production and integrate advanced technologies throughout the operations
“Siloed procurement is a big problem. We’ve recently worked with a client where a CDMO was selected simply because it could start two weeks before another. Ultimately, that led to about an 18-month delay in the project altogether.” Matthew Holt,
“Outsourcing is about giving the things you don’t excel at to someone who does them exceptionally well. That’s what speeds development and delivery,” says Kindeva’s CEO, Milton Boyer. Milton brings nearly 30 years of pharmaceutical manufacturing experience as a contract
As the pharmaceutical industry grapples with geopolitical tensions, regulatory shifts, and technological disruption, the question of what constitutes a strong external partnership has never been more critical. We asked industry leaders across CDMOs, biotechs, and technology providers to share their
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
